Controlled comparison of milnacipran and fluoxetine in major depression

Autor: Patrick Papart, J. M. Devoitille, Jules de Wilde, Michel Bataille, F. Bartholomé, Michel Dufrasne, C. Mertens, Henri Gilson, Marc Ansseau, Pierre Krémer, Michel Schittecatte, Andre De Nayer, B. Troisfontaines, C. Serre, Gérard Charles, Jean-Luc Evrard, P. Darimont
Rok vydání: 1994
Předmět:
Zdroj: Psychopharmacology. 114:131-137
ISSN: 1432-2072
0033-3158
DOI: 10.1007/bf02245454
Popis: The efficacy and the tolerance of milnacipran (100 mg/day), a second generation antidepressant which equipotently inhibits both noradrenaline and serotonin reuptake, was compared to fluoxetine (20 mg/day), a selective serotonin reuptake inhibitor, in two parallel groups of, respectively, 97 and 93 major depressive outpatients. The duration of the study was 6 weeks, with assessments every 2 weeks by means of the Montgomery and Asberg depression scale (MADRS), the Hamilton depression scale, the clinical global impressions (CGI), and a checklist of symptoms and side-effects. Results showed significant superiority of fluoxetine over milnacipran on most rating instruments: MADRS (P = 0.01) including five individual items, Hamilton depression scale (P = 0.002) including ten individual items, CGI of severity (P = 0.01) and therapeutical index (P = 0.002). On visual analogue scales assessing the clinical profile of the compounds, fluoxetine was rated as exhibiting more psychostimulating activity than milnacipran (P = 0.0008). The tolerance of the two antidepressants was very similar, with the exception of symptoms of dizziness which were more frequently reported with milnacipran (P = 0.01). These differences in efficacy favoring fluoxetine could result from the selection of a dose of milnacipran below the optimal therapeutic dose for this type of psychiatric patients or to the administration of the compounds in single daily intakes, whereas milnacipran possesses a plasma elimination half-life of only 7 h.
Databáze: OpenAIRE
Externí odkaz: